Chile
Tuberculosis profile
Population  2012 17 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.21 (0.21–0.22) 1.2 (1.2–1.2)
Mortality (HIV+TB only) 0.012 (<0.01–0.015) 0.07 (0.05–0.08)
Prevalence  (includes HIV+TB) 3.6 (1.4–6.7) 21 (8.3–38)
Incidence  (includes HIV+TB) 2.8 (2.4–3.1) 16 (14–18)
Incidence (HIV+TB only) 0.084 (0.074–0.095) 0.48 (0.42–0.54)
Case detection, all forms (%) 87 (77–99)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 1 173 (53) Relapse 165 (71)
Smear-negative 536 (24) Treatment after failure 4 (2)
Smear-unknown / not done 2 (<1) Treatment after default 33 (14)
Extrapulmonary 518 (23) Other 29 (13)
Other 0 (0)      
Total new 2 229   Total retreatment 231  
           
Other (history unknown) 0        
Total new and relapse 2 394   Total cases notified 2 460  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.1 1.8 1.3
Age < 15 8 26 15
Laboratories 2012
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 11.2
Drug susceptibility testing (per 5 million population) 0.3
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 71   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary    
Retreatment 43  
TB/HIV 2012 Number (%)
TB patients with known HIV status 392 (16)
HIV-positive TB patients 140 (36)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.69 (0.25–1.5) 2.9 (0.95–6.7)
MDR-TB cases among notified pulmonary
TB cases
12 (4–26) 7 (2–15)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 125 (8%) 172 (74%) 365
Laboratory-confirmed MDR-TB cases 12 5 18
Patients started on MDR-TB treatment     8
Financing TB control 2013
National TB programme budget (US$ millions) <1
% Funded domestically 100%
% Funded internationally  
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-23 Data: www.who.int/tb/data